E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute lymphoblastic and myeloid leukemia |
Leucemia linfoide y mieloide aguda |
|
E.1.1.1 | Medical condition in easily understood language |
lymphoblastic and myeloid leukemia |
Leucemia linfoide y mieloide |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000842 |
E.1.2 | Term | Acute lymphatic leukaemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Comparison of cumulative incidence of chronic cGVHD (localized or extended) after allogeneic peripheral blood stem cell donor from HLA-identical with or without ATeGe-Fresenius as revised Seattle criteria of Lee et al. |
Comparación de incidencia acumulada de EICH crónica (localizada o extensa) posterior a trasplante alogénico de progenitores hematopoyéticos de sangre periférica procedente de donante HLA-idéntico con o sin ATeGe-Fresenius según la revisión de Seattle de los criterios de Lee et al. |
|
E.2.2 | Secondary objectives of the trial |
-Comparison of acute cGvHD on day +100 after transplantation. -Comparison of quality of life between both treatment arms according to the EORTC. -Comparison of treatment-related mortality on day +100 and day +365 after allogeneic peripheral blood stem cell transplantation. -Comparison of toxicity according to the Bearman-Score. -Comparison of overall survival post-transplant at two years. -Comparison of progression-free survival post-transplant at two years. -Comparison of engraftment (leukocyte count > 1.0 x 109/l, platelet count > 20 x 109/l). -Comparison of incidence of bacterial, viral, fungal and protozoal infection at day +100 and at one year after transplantation. -Comparison of chronic-GvHD-free survival between the two treatment arms at two years. -Incidence of adverse events (AEs) and adverse drug reactions (ADRs) between the two treatment arms. |
- Comparación de EICH aguda el día +100 posterior al trasplante. - Comparación de calidad de vida entre ambos grupos de tratamiento. - Comparación de mortalidad asociada al tratamiento el día +100 y el día +365 posterior a TPH alogénico. - Comparación de la toxicidad. - Comparación de supervivencia global post-trasplante a los dos años. - Comparación de supervivencia sin evidencia de progresión de la enfermedad a los dos años. - Comparación del tiempo de recuperación hematopoyética (número de leucocitos> 1.0x109/l, número de plaquetas >20x 109/l) - Comparación de incidencia de infección bacteriana, vírica, micótica y por protozoos el día +100 y un año posterior al trasplante. - Comparación de supervivencia libre de EICH crónica entre los grupos de tratamiento a los dos años post-trasplante. - Incidencia de efectos adversos y reacciones adversas entre los grupos de tratamiento. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Analysis of genetic polymorphism of the gene NOD2/CARD15 and KIR-genes and related genes to predict graft-versus-host disease and transplant-associated complications. |
El análisis de polimorfismo genético del gen NOD2/CARD15 y KIR genes y genes relacionados con la predicción de injerto contra huésped crónica y trasplante asociado complicaciones |
|
E.3 | Principal inclusion criteria |
Acute myeloid leukemia in first or subsequent complete remission (de-novo or secondary AML). Acute lymphoblastic leukemia in first or subsequent complete remission. Patient's age: 18 ? 65 years. Myeloablative standard conditioning. HLA-identical sibling (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1). No major organ dysfunctions. Patient's written informed consent |
LMA en primera o subsiguiente remisión completa (RC1 y > RC1). LLA en primera o subsiguiente remisión completa. Edad del paciente: 18-65 años. En régimen de preparación mieloablativo. HLA-idénticos (HLA-A, HLA-B, HLA-DRBI y HLA-DQB1). No disfunción orgánica mayor. Pacientes que hayan firmado consentimiento informado. |
|
E.4 | Principal exclusion criteria |
No complete remission at time of randomization. Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as: o Total bilirubin, SGPT or SGOT > 5 times upper the normal level. o Left ventricular ejection fraction < 30 %. o Creatinine clearance < 30 ml/min. o DLCO < 35 % and/or receiving supplementary continuous oxygen. Positive serology for HIV. Pregnant or lactating women. Serious psychiatric or psychological disorders. Progressive invasive fungal infection at time of registration. |
No remisión completa en el momento de la aleatorización Enfermedad severa irreversible renal, hepática, pulmonar o cardiaca con: o Bilirrubina total, GOT o GPT > 5 veces el nivel normal o Fracción de eyección del ventrículo izquierdo < 30% o Aclaramiento de creatinina < 30ml/min o DLCO < 35% y/o receptores de oxigenoterapia continua Serología positiva a VIH Mujer embarazada o en periodo de lactancia Enfermedades psiquiátricas o psicológicas graves Infección micótica progresiva invasiva en el momento del registro |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Comparison of cumulative incidence of chronic GvHD (limited or extensive) after allogeneic peripheral blood stem cell transplantation from HLA-identical siblings with or without anti-T-lymphocyte-globulin according to the revised Seattle criteria of Lee et al. and of the NIH Consensus Development Project at two years after transplantation. |
La comparación de incidencia acumulada de EICH crónica (limitada o extensa), después de alogénico de células madre de sangre periférica trasplante de hermanos HLA idénticos con o sin anti-linfocitos T-globulina de acuerdo a los criterios revisados de Seattle de Leeet al. y del Proyecto de Desarrollo de Consenso del NIH, dos años después trasplante. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Two years after transplantation. |
Dos años después del trasplante |
|
E.5.2 | Secondary end point(s) |
See secondary objectives |
Ver objetivos secundarios |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
See secondary objectives |
Ver objetivos secundarios |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 31 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |